Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
PTCT submitted a Form 144 notice for the proposed sale of 65 common shares associated with restricted stock vesting on 02/17/2026. The filing also lists multiple insider sales during the prior three months by Neil G. Almstead and Zheng Y. Almstead, with individual transactions dated 11/24/2025 through 01/08/2026 and share amounts and gross proceeds disclosed for each trade.
PTCT submitted a Form 144 reporting a proposed sale of 3,056 common shares tied to restricted stock vesting on 02/17/2026. The filing also lists recent open-market sales by insiders, including Neil G. Almstead (examples shown: 35,572 shares on 11/24/2025 and 71,928 shares on 11/25/2025). The transactions are presented as issuer compensation and past sales over the prior three months.
PTCT — Pierre S. Szyika-Gravier filed a Form 144 to sell 2,992 common shares. The filing lists the sale date as 02/17/2026 and describes the securities as restricted stock vesting related to compensation. The notice also reports a prior sale of 2,139 shares on 01/06/2026.
PTCT filed a Form 144 reporting a proposed sale of 2,494 common shares arising from restricted stock vesting on 02/17/2026. The filing also lists recent dispositions by Christine Utter: 1,381 shares on 01/06/2026, 1,235 shares on 01/07/2026, and 1,034 shares on 01/08/2026, with reported proceeds for each trade.
Mark Boulding reported sales of company common stock. The filing lists 3,081 shares tied to restricted stock vesting dated 02/17/2026 and executed through Fidelity Brokerage Services LLC. The filing also itemizes prior dispositions in January 2026: 2,266 (01/05/2026), 1,739 (01/06/2026), 4,879 (01/07/2026), 4,033 (01/08/2026), and 2,314 (01/09/2026).
PTCT submitted a Form 144 reporting a proposed sale of 2,484 common shares tied to restricted stock vesting on 02/17/2026. The filing also lists three prior open-market sales by Lee S. Golden: 1,340 shares on 01/06/2026, 642 shares on 01/07/2026, and 866 shares on 01/08/2026
PTCT reported Form 144 sale notices for common stock by Matthew Klein. The filings list multiple sales of common shares in December 2025 and January 2026, including specific transactions of 12/02/2025 (3,428 shares) and 12/30/2025 (8,089 shares). The entries show proceeds for each sale in U.S. dollars.
An affiliate of PTCT filed a notice of proposed sale under Rule 144 for 2,813 common shares, to be sold through Fidelity Brokerage Services on NASDAQ at an aggregate market value of 194,490.82. Shares outstanding were 80,288,305 as of the filing. The seller acquired these shares on 02/17/2026 via an option granted on 02/15/2024, paid in cash. Over the prior three months, the same holder reported several additional common share sales, including 4,879 shares on 01/07/2026 for gross proceeds of 377,839.55 and 4,033 shares on 01/08/2026 for 308,761.28.
Janus Henderson Group plc reported beneficial ownership of 4,851,332 shares of PTC Therapeutics, Inc. common stock, representing 6.0% of the class as of 12/31/2025. All voting and dispositive power over these shares is shared, with no sole authority reported.
The position arises through multiple Janus Henderson asset management subsidiaries that exercise investment and/or voting discretion for various managed portfolios. Those managed portfolios receive all dividends and sale proceeds from the shares, and no single portfolio holds more than five percent of PTC Therapeutics’ common stock. Janus Henderson certifies the holdings are passive and not for influencing control.
The Toronto-Dominion Bank has reported a significant ownership stake in PTC Therapeutics, Inc. The bank beneficially owns 4,138,215 shares of PTC Therapeutics common stock, representing 5.2% of the outstanding class as of 12/31/2025.
TD Bank reports sole power to vote and dispose of all 4,138,215 shares, with no shared voting or dispositive power. The bank states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PTC Therapeutics.